Clinical trials: Plaque Psoriasis Vulgaris
Plaque Psoriasis
Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis
There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment.
- Trial name
- NCT01710046
- Testing
- (CP-6890,550) Tofacitinib, (CP-690,550) Tofacitinib
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Pfizer
Psoriasis Vulgaris
Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Stasis Syndrome
We designed this study as a multicenter, randomized, double blinded and placebo-controlled clinical trial. The aim of the study is to evaluate the clinical efficacy, safety and control of recurrence rate of psoriasis with blood…
- Trial name
- NCT03942198
- Testing
- Taodan Granules
- Where
- 5 sites in China
- Volunteers
- 216 people
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Psoriasis, Psoriasis Palmaris
Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines
French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults have been developed by the psoriasis research group of the French Society of Dermatology using literature available until July 2017…
- Conditions
- Psoriasis, Psoriasis Palmaris, Psoriasis Inverse, Psoriasis Vulgaris
- Trial name
- NCT05144165
- Testing
- Experts consensus
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre of Evidence of the French Society of Dermatology
Psoriasis Vulgaris
An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris
The purpose of the study is to compare the 3 ointment formulations containing LEO 29102 plus calcipotriol and Daivonex® ointment and Diprosone® ointment and to compare LEO 29102 plus calcipotriol to LEO 29102 alone and to…
- Trial name
- NCT01466478
- Testing
- Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment, Ointment B: LEO 29102 2.5 mg/g ointment, Ointment C: Calcipotriol 50 µg/g ointment
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This Phase II clinical study is to test safety and efficacy of BT061 against psoriasis given as repeated doses.
- Trial name
- NCT01072383
- Testing
- BT061
- Where
- 13 sites in Czechia, Hungary
- Volunteers
- 49 people
- Sponsor
- Biotest
Psoriasis
Excimer Laser With Topical Agents in Psoriasis Vulgaris
Psoriasis is a chronic, immune-mediated disease that affects approximately 2% of the population. The development and exacerbation of psoriasis involve an interaction between multiple genetic and environmental risk factors.
- Trial name
- NCT05555797
- Testing
- 308nm Excimer laser, Tazarotene Topical Gel, Betamethasone Valerate
- Volunteers
- 30 people
- Sponsor
- Assiut University
Psoriasis Vulgaris
Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis
This was a Phase I, single-center, randomized, controlled trial to evaluate the antipsoriatic efficacy of calcipotriol in novel formulations based on AKVANO technology as compared to marketed calcipotriol products (Daivonex®…
- Trial name
- AKVANO-AKP01 (NCT05488990)
- Testing
- AKVANO-Calcipotriol formulation 1, AKVANO-Calcipotriol formulation 2, AKVANO vehicle formulation 1
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Lipidor AB
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Psoriasis Vulgaris
To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%…
- Trial name
- NCT03731091
- Testing
- Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%, Enstilar® foam (LEO Pharma Inc.)
- Where
- 30 sites in United States
- Volunteers
- 494 people, healthy volunteers welcome
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Chronic Plaque Psoriasis
Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris
Ultra-violet light B (UVB) therapy has been used by dermatologists to treat psoriasis for decades. Only a few studies have begun to dissect the mechanism of how NB-UVB therapy causes lesion resolution.
- Trial name
- NCT00844363
- Testing
- NB-UVB
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rockefeller University
Psoriasis
Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)
This is an open-label, multicenter, parallel-group comparison study of the efficacy, safety, and tolerability of infliximab therapy in adult patients suffering from chronic plaque psoriasis (psoriasis vulgaris).
- Trial name
- NCT00254982
- Testing
- Infliximab
- Volunteers
- 593 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis Vulgaris, Koebner Phenomenon
PSODEEP2 Pilot Study on Koebner Induction in Psoriasis
Patients (n=15) with skin psoriasis, minimum age 18 years, without systemic immunomodulatory treatment will be subject to Koebner induction on arms and legs given that they have given written consent and that they have…
- Trial name
- PSODEEP2PIL (NCT06414382)
- Testing
- Tape-stripping
- Volunteers
- 15 people
- Sponsor
- Skane University Hospital
Psoriasis
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
Evaluate psoriasis severity and its psychosocial impact using a novel Patient Reported Outcome (the Simplified Psoriasis Index SPI) at 16 weeks, as well as long-term safety, tolerability and efficacy of secukinumab administered…
- Trial name
- IPSI-PSO (NCT02595970)
- Testing
- Secukinumab
- Where
- 17 sites in France
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris, Psoriatic Arthritis
A Phase 3 Clinical Study of KHK 4827
This study is designed to evaluate the safety and efficacy of long-term exposure to KHK4827 in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic erythroderma) who have completed Study 4827-003 (Study 003)and in…
- Conditions
- Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris, Psoriatic Erythroderma
- Trial name
- NCT02052609
- Testing
- KHK4827 140mg SC, KHK4827 210mg SC
- Where
- Japan
- Volunteers
- 155 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Psoriasis
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01163253
- Testing
- CP-690,550
- Where
- 323 sites in United States, Argentina and 34 more
- Volunteers
- 2,867 people
- Sponsor
- Pfizer
Psoriasis Vulgaris
An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A
The purpose of this study is to evaluate the anti-psoriatic effect of injected Botulinum toxin type A compared to that of injected vehicle.
- Trial name
- NCT02577185
- Testing
- Botulinum Toxin Type A, Sodium chloride 9 mg/ml
- Where
- 2 sites in Denmark
- Volunteers
- 10 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris
The purpose of this study is to evaluate the antipsoriatic effect of 5 different combinations of calcipotriol plus betamethasone dipropionate in Daivobet® gel vehicle in compared to Daivobet® gel in order to explore/find other…
- Trial name
- NCT01837576
- Testing
- Calcipotriol plus BDP gel in different doses
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris, Psoriasis
Tofacitinib Ointment For Chronic Plaque Psoriasis
The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested.
- Trial name
- NCT01831466
- Testing
- tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g
- Where
- 54 sites in United States, Canada and 2 more
- Volunteers
- 476 people
- Sponsor
- Pfizer
Plaque Psoriasis, Psoriasis Vulgaris
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
The trial investigates the efficacy and safety of brodalumab against guselkumab in treatment for patients with moderate-to-severe plaque psoriasis who still have some remaining symptoms after ustekinumab treatment.
- Conditions
- Plaque Psoriasis, Psoriasis Vulgaris, Psoriasis
- Trial name
- COBRA (NCT04533737)
- Testing
- Brodalumab, Guselkumab
- Where
- 65 sites in Austria, Belgium and 10 more
- Volunteers
- 113 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris
The purpose of this study is to evaluate the anti-psoriatic effect of Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes), Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes) compared with…
- Trial name
- NCT01607853
- Testing
- Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes), Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes), Daivobet® gel applied for 24 hours (+/- 2 hours)
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma